Strides Pharma Science share news and announcements
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Formerly Strides Shasun
Last close ₹1,014.80up ₹16.40 (1.64%)BSE ₹1,012.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹998.40.
52-week range of traded prices to 23 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹9,354 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 31 Jul 2026
- 15.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 Jul 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.49%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 31 Jul 2026
- 21.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 31 Jul 2026
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 Jul 2026
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,12,38541.2% delivered
Strides Pharma Science share news and announcements
1,456 announcements, routine notices left out, newest first. Page 28 of 30.
Aug 2008
1 Aug · Business
Press release dated August 01, 2008, titled "Strides completes acquisition of controlling interest in Ascent Pharmahealth Limited (formely Genepharm Australasia Limited). Emerges as Australia's 4th largest Generic Company . Australasia becomes USD 90 Million operation for Strides". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
25 Jul · Grant of Options
Strides Arcolab Limited had informed the Exchange that : "The Remuneration Committee of the Company on July 22, 2008 has granted 7,15,000 options under the Strides Arcolab ESOP 2008 at Rs. 122.15/- per option (exercise price), to few Eligible Employees of the Company. The shares covered by such options are 7,15,000 equity shares. The vesting period of these options is in a phased manner over a period of three years. The options may be exercised within a period of 30 days from the date of vesting". The Company has now informed the Exchange regarding grant of options under Strides Arcolab ESOP 2008 Scheme wherein Company had inadvertently mentioned the number of options granted '715,000' instead of '665,000'.23 Jul · Business
Press release dated July 23, 2008, titled "Strides/Aspen Joint Venture; In-Licensing Deal with GSK". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jul · Grant of Options
The Remuneration Committee of the Company on July 22, 2008 has granted 7,15,000 options under the Strides Arcolab ESOP 2008 at Rs. 122.15/- per option (exercise price), to few Eligible Employees of the Company. The shares covered by such options are 7,15,000 equity shares. The vesting period of these options is in a phased manner over a period of three years. The options may be exercised within a period of 30 days from the date of vesting22 Jul · Results
Standalone Results for the half year ended on 30-JUN-2008 as follows: Net Sales of Rs. 28046.21 lacs for half year ending on 30-JUN-2008 against Rs. 21129.3 lacs for the half year ending on 30-JUN-2007. Net Profit / (Loss) of Rs. (7200.91) lacs for the half year ending on 30-JUN-2008 against Rs. 1794 lacs for the half year ending on 30-JUN-2007.22 Jul · Business
Press release dated July 22, 2008, titled "Q2'08 Revenue up - 49% to Rs. 269 Cr.; EBITDA at Rs. 55 Cr. - Up 176%; PAT Impacted by Exceptional items". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jul · Results
Consolidated Results for the half year ended on 30-JUN-2008 as follows: Net Sales of Rs. 46233.1 lacs for half year ending on 30-JUN-2008 against Rs. 34142.3 lacs for the half year ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 375.09 lacs for the half year ending on 30-JUN-2008 against Rs. 1765.5 lacs for the half year ending on 30-JUN-2007.22 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 16077.45 lacs for quarter ending on 30-JUN-2008 against Rs. 10522.1 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. (5596.11) lacs for the quarter ending on 30-JUN-2008 against Rs. 1018.1 lacs for the quarter ending on 30-JUN-2007.22 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 25535.33 lacs for quarter ending on 30-JUN-2008 against Rs. 17989.9 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. (4884.26) lacs for the quarter ending on 30-JUN-2008 against Rs. 1158.3 lacs for the quarter ending on 30-JUN-2007.21 Jul · Meeting
Minutes of the Annual General Meeting of the members of the Company held on June 27, 2008. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2008.
Jun 2008
26 Jun · Business
Press release dated June 26, 2008, titled "Strides Arcolab receives ANDA approvals for Famotidine Injection USP 10 mg/ml-2mL and 4mL & 20mL". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jun · Results
Based on the Scrutinizer's Report dated June 18, 2008, the special resolutions seeking approval of the shareholders through Postal Ballot concerning the following matters have been carried out with requisite majority. (1) Inter-Corporate investment under section section 372A of the Companies Act 1956 for investment of upto Rs. 60 Crores in Onco Therapies Limited. (2) Inter-Corporate investment under section 372A of the Companies Act, 1956 for investment of upto USD 800,000 in Akorn Strides LLC, USA. (3) Strides Arcolab Employee Stock Option Plan- 2008. (4) Extension of Strides Arcolab Employee Stock Option Plan - 2008 to employees of Subsidiary Companies. (5) Amendment to Strides Arcolab Employee Stock Option Plan 2006.17 Jun · Allotment of Equity Shares
The Company has allotted 10,45,725 fully paid equity shares of Rs.10/- each at a price of Rs.400/- per share, against conversion of equivalent number of Fully Convertible Debentures, to Blissup Holdings Limited. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 39,00,42,890 consisting of 39,004,289 equity shares of Rs.10/- each to Rs.40,05,00,140 consisting of 4,00,50,014 equity shares of Rs.10/- each12 Jun · Meeting
Notice of Annual General Meeting of the Company to be held on June 27,2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2008
28 May · Limited Review Report
Auditor's have conducted the limited review of the Unaudited financial results for the quarter ended March 31, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 May · Meeting
Register of Members and Transfer Books of the Company will remain closed from June 21, 2008 to June 27, 2008 (both days inclusive), in connection with the ensuing Annual General Meeting (AGM) of the Company convened to be held on June 27, 2008.28 May · Updates
Abstract and Memorandum of Interest circulated to the shareholders pursuant to section 302 of the Companies Act, 1956 informing revision in remuneration of Managing Director. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 May · Business
Press release dated May 23, 2008, titled "Strides Arcolab receives ANDA approval for Rifampicin for Injection USP, 600 mg/ vial". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 May · Meeting
Pursuant to section192A (2) of the Companies Act, 1956 read with Companies (Passing of the resolution by Postal Ballot) Rules, 2001, the following resolutions for approval of the Shareholders through Postal Ballot: 1) Special Resolution pursuant to Section 372A of the Companies Act, 1956 for Inter-Corporate Investment of upto Rs. 60 Crores in Onco Therapies Limited. 2) Special Resolution pursuant to Section 372A of the Companies Act, 1956 for Inter-Corporate Investment of upto USD 800,000 in Akorn Strides LLC, USA. 3) Special Resolution to accord approval to the Strides Arcolab- ESOP 2008. 4) Special Resolution to accord approval to extending the Strides Arcolab- ESOP 2008 to permanent employees of the Company's subsidiaries. 5) Special Resolution to amend Strides Arcolab- ESOP 2006. The Company has appointed Mr. Gigi Joseph K.J., Practicing Company Secretary of M/s. SGS Company Secretaries, Bangalore as Scrutinizer for conducting the Postal Ballot process in a fair and transparent manner. The duly completed Postal Ballot forms should reach the Scrutinizer on or before the close of working hours on June 16, 2008. The Scrutinizer will submit his report after completion of the Scrutiny and the results of the Postal Ballot will be announced on June 18, 2008. A copy of the notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 May · Business
Press release dated May 14, 2008, titled "Strides Arcolab receives ANDA approval for Flumazenil Injections USP, 0.1 mg/ml multiple dose vial". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
30 Apr · Business
Press release dated April 30, 2008, titled "Strides & Genepharm signs definitive agreements-Update on final transaction terms". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Business
Press release dated April 28, 2008, titled "Strides Arcolab Q1 08 Global Revenues Grow to Rs.278 crores (USD 69.50 million); PAT of Rs.52.60 crores (USD 13.15 million); Results in line with Guidance". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 11968.8 lacs for quarter ending on 31-MAR-2008 against Rs. 10607.3 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. (1604.8) lacs for the quarter ending on 31-MAR-2008 against Rs. 776 lacs for the quarter ending on 31-MAR-2007.28 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 20697.8 lacs for quarter ending on 31-MAR-2008 against Rs. 16152.4 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 5259.4 lacs for the quarter ending on 31-MAR-2008 against Rs. 607.2 lacs for the quarter ending on 31-MAR-2007.24 Apr · Business
Press release dated April 24, 2008, titled "Strides Arcolab receives 2 ANDA approvals for Ondansetron Injection USP, 2 mg/ml (20 ml vials) and 2 mg/ml (2 ml vials)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Apr · Board meeting
Meeting on 28 Apr 2008: “Unaudited Financial Results for the qtr ended March 31, 2008”8 Apr · Legal
Vide its letter dated April 08, 2008 that "We refer to a news item carried out by News Channel, today afternoon on 'dilution of stake by Promoters' and 'bidding by Nicholas Piramal' group. We strongly deny any such development and wish to state that the news is not factual and is purely speculative. On the contrary, the Promoters have increased their stake recently, which has also been disclosed to the Stock Exchanges and is in the public domain".4 Apr · Grant of Options
The Remuneration Committee of the Company on March 31, 2008 has granted 6,00,000 options under the Strides Arcolab ESOP 2006 at Rs. 133/- per option (exercise price), to few Eligible Employees of the Company. The shares covered by such options are 6,00,000 equity shares. The vesting period of these options is in a phased manner over a period of four years. The options may be exercised within a period of 30 days from the date of vesting.
Mar 2008
19 Mar · Business
Press release dated March 19, 2008, titled "Strides Arcolab receives its third injectable ANDA approval for Fosphenytoin Injection 50mg/mL". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Business
Vide its letter dated March 12, 2008 regarding a press release dated March 11, 2008, titled "Strides Arcolab receives USFDA approval for its Penicillin Sterile Facility in Bangalore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Business
Press release dated March 12, 2008, titled "Strides Arcolab receives its second injectable ANDA approval for Tobramycin 40 mg/ mL". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Business
Press release dated March 12, 2008, titled "Strides Arcolab receives Health Canada approval for Tazo Pip Injection". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Mar · Business
Strides Arcolab Limited had informed the Exchange on March 11, 2008 that: "Further to the press release issued by the Company on March 05, 2008 on the closure of Aspen transaction, the Strides Aspen JV today announced the following clarifications: (1) Mr. V Madhusudhan will be CEO of Cellofarm - the Brazilian operation of the JV and Regional Director of the Latin American operations for the JV. Mr. V. Madhusudhan will be appointed to the Board of Strides Aspen JV and will report to the Board of Directors of the JV Company. (2) Mr. Praveen Venkataramanan will lead the rest of the Latin America and Mexico Operations and will report into Mr. V. Madhusudhan." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Mar · Updates
Strides Arcolab Limited had informed the Exchange regarding the press release issued by them dated March 07, 2008 on the occasion of release of Audited financial results for the year ended December 31, 2007. The Company has now informed the Exchange that: "We had inadvetently made a typographical error in the last paragraph of the first page of the press release under the 'Key highlights' which should read as: Cash & Cash equivalents at closing of the Aspen Transaction as at 7th March 08 were Rs.3200 milion (US$ 80 million) Instead of: " Cash & Cash equivalents at closing of the Aspen Transaction as at 7th March 08 were Rs.1840 million (US$ 46 million)".10 Mar · Disclosure
The Board of Directors have approved the introduction of a new ESOP Scheme titled 'Strides Arcolab ESOP-2008' for issuance of upto 1,500,000 options, subject to applicable Statutory / regulatory requirements10 Mar · Allotment of Equity Shares
The Company has allotted 40,00,000 fully paid equity shares of Rs.10/- each at a price of Rs. 400/- per share ,against conversion of equivalent number of Fully Convertible Debentures, to Dobliss Holding Limited (31,11,440 shares) and Blissup Holding Limited (8,88,560 shares). Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs.35,00,42,890 consisting of 35,004,289 equity shares of Rs.10/- each to Rs. 39,00,42,890 consisting of 3,90,04,289 equity shares of Rs.10/- each7 Mar · Management
Auditor's report for the financial year ended December 31, 2007. A Copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Mar · Results
Standalone Results for the year ended on 31-DEC-2007 as follows: Net Sales of Rs. 39291.5 lacs for year ending on 31-DEC-2007 against Rs. 45508.8 lacs for the year ending on 31-DEC-2006. Net Profit / (Loss) of Rs. (11521.4) lacs for the year ending on 31-DEC-2007 against Rs. 3618.41 lacs for the year ending on 31-DEC-2006.7 Mar · Results
Standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 7575.8 lacs for quarter ending on 31-DEC-2007 against Rs. 12920.8 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. (13340.4) lacs for the quarter ending on 31-DEC-2007 against Rs. 1296.91 lacs for the quarter ending on 31-DEC-2006.7 Mar · Results
Consolidated Results for the year ended on 31-DEC-2007 as follows: Net Sales of Rs. 72561.2 lacs for year ending on 31-DEC-2007 against Rs. 74298.4 lacs for the year ending on 31-DEC-2006. Net Profit / (Loss) of Rs. (5012.1) lacs for the year ending on 31-DEC-2007 against Rs. 4022.9 lacs for the year ending on 31-DEC-2006.7 Mar · Updates
Pursuant to clause 20 of the listing agreement the Company has submitted to the Exchange the details on Audited Accounts for the Year ended December 31, 2007. A Copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Mar · Board meeting
Board of Directors, at its meeting held on March 07, 2008 has not recommended any dividend for the year ended December 31, 2007.7 Mar · Business
Press release dated March 07, 2008, titled "Strides Arcolab FY 07 Global Revenues Grow To Rs.8648 million ( US$ 216 million)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Mar · Business
Press release dated March 05, 2008, titled "Strides Arcolab-India and Aspen-South Africa Announce Successful Completion of the Latin American Transaction". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
28 Feb · Board meeting
To consider inter-alia, the audited financial results of the company for the financial year ended December 31, 2007 and recommendation of dividend if any.8 Feb · Business
Press release dated February 08, 2008, titled "Strides Arcolab, India and Genepharm, Australia Enter Into A Broad and Strategic Partnership For The Australasian Markets Through A Series of Transactions". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
24 Jan · Results
The Company will declare and publish the Audited Financial Results for the financial year ended December 31, 2007 before March 31, 2008. In view of the same, the Company would not be declaring and publishing the Unaudited Financial Results for the last quarter ended December 31, 2007 during the month of January, 20089 Jan · Business
Press release dated January 09, 2008, titled "Strides Arcolab discontinues manufacturing operations in its New Jersey facility". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jan · Updates
Mr.K.R. Ravishankar ceased to be an Executive Director of the Company w.e.f. 1st January 2008. However , he will continue to remain as Director on the Board of Directors of the Company